Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | GHRHR | Q02643 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL121908 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL14060916 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189598 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL121909 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189599 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301509 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL7109515 | 0.99 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL7109517 | 0.99 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL25052982 | 0.99 | NPC1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL22667521 | 0.99 | NPC1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156774-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-05-16 | — | — | US | claimed |
| EP-4302754-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2024-01-10 | — | — | EP | claimed |
| WO-2022184164-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | WO | claimed |
| CN-115025053-A | Stable docetaxel albumin nanoparticle composition | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-20240156774-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-05-16 | — | — | US | disclosed |
| EP-4302754-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023109904-A1 | COMBINATION OF DOCETAXEL ALBUMIN COMPOSITION AND VEGF INHIBITOR OR VEGFR INHIBITOR AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-116265015-A | Combination of docetaxel albumin composition and VEGF inhibitor or VEGFR inhibitor and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-115400115-A | Combinations of docetaxel albumin compositions and immune checkpoint inhibitors and uses | 石药集团中奇制药技术（石家庄）有限公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2022184164-A1 | STABLE DOCETAXEL ALBUMIN NANOPARTICLE COMPOSITION | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-115025053-A | Stable docetaxel albumin nanoparticle composition | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-103054798-B | Compositions and methods for preparing poorly water soluble drugs with increased stability | 阿布拉科斯生物科学有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20100099897-A1 | STABLE ANHYDROUS CRYSTALLINE DOCETAXEL AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2010-04-22 | — | — | US | disclosed |
| EP-2155709-A1 | STABLE ANHYDROUS CRYSTALLINE DOCETAXEL AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2010-02-24 | — | — | EP | disclosed |
| US-20090196933-A1 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY | ABRAXIS BIOSCIENCE, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2008123737-A1 | DOCETAXEL / MONO PROPYLENE GLYCOL CLATHRATE AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123751-A1 | STABLE ANHYDROUS CRYSTALLINE DOCETAXEL AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2008-10-16 | — | — | WO | disclosed |
| EP-1928435-A2 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY | Abraxis BioScience, LLC. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070082838-A1 | Compositions and methods for preparation of poorly water soluble drugs with increased stability | ABRAXIS BIOSCIENCE, INC. (US) | 2007-04-12 | — | — | US | disclosed |
| WO-2007027941-A2 | COMPOSITIONS AND METHODS FOR PREPARATION OF POORLY WATER SOLUBLE DRUGS WITH INCREASED STABILITY | ABRAXIS BIOSCIENCE, LLC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099897-A1 | STABLE ANHYDROUS CRYSTALLINE DOCETAXEL AND METHOD FOR THE PREPARATION THEREOF | MCL1, TALDO1, BCL9 | TUBB4A 43/4885TUBB 68/4885TUBA3C 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.